MoonLake Immunotherapeutics (MLTX) said Wednesday that it has screened patients for for three new clinical trials targeting three new indications to assess sonelokimab, an investigational Nanobody aimed at treating inflammatory diseases.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa, or HS, palmoplantar pustulosis, or PPP, and axial spondyloarthritis, or axSpA, along with adult patients suffering from HS and active psoriatic arthritis, or PsA.
The new trials include the phase 3 VELA-TEEN trial in adolescent HS, which will evaluate safety and tolerability over 24 weeks in 30 to 40 adolescents; the phase 2 LEDA trial in PPP, assessing the efficacy of a 120mg subcutaneous dose in around 30 patients; and the phase 2 S-OLARIS trial in axSpA, using Positron Emission Tomography and Magnetic Resonance Imaging, or PET/MRI imaging to measure inflammation reduction in 25 patients, the biotechnology company said.
Shares of MoonLake were down 0.4% in recent Wednesday trading.
Price: 50.00, Change: -0.22, Percent Change: -0.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。